Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference [Accessibility Statement] Skip NavigationSECAUCUS, N.J., Feb. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, ...

Core Insights - Quest Diagnostics Incorporated (DGX) is a leader in diagnostic information services, providing a range of testing for various health conditions [1][2] - The company has a market capitalization of $20.31 billion, classifying it as a "large-cap" stock [2] Financial Performance - In Q3 2025, DGX reported net revenues of $2.82 billion, a 13.1% year-over-year increase, surpassing analysts' expectations of $2.72 billion [5] - The company's adjusted EPS rose by 13% year-over-year to $2.60, exceeding the expected $2.51 [5] - Following strong results, DGX raised its fiscal 2025 net revenue guidance to a range of $10.96 billion to $11 billion and adjusted EPS guidance to $9.76 to $9.84 [6] Stock Performance - DGX's shares reached a 52-week high of $197.55 in October but have since declined by 7.6% [3] - Over the past three months, DGX's stock has seen a marginal decline, while the State Street Health Care Select Sector SPDR ETF (XLV) gained 11.6% [3] - In the last six months, DGX's stock gained approximately 2%, compared to a 12.6% rise in the ETF [4] - Over the past 52 weeks, DGX's stock increased by 17%, outperforming the Health Care ETF's 9.3% return [4]

Core Insights - Quest Diagnostics will present its strategy, performance, and market trends at the Jefferies Healthcare Services Conference on September 29, 2025 [1] - The presentation will include a live webcast available on the company's investor relations page, with an archived version accessible for 24 hours post-event [2] - Quest Diagnostics serves a significant portion of the U.S. population, providing diagnostic insights that empower health management [3] Company Overview - Quest Diagnostics is a leader in diagnostic information services, aiming to improve health outcomes through laboratory testing [3] - The company operates one of the largest databases of de-identified clinical lab results, which aids in disease identification and treatment [3] - Annually, Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the U.S. [3] Recent Developments - Quest Diagnostics has launched an advanced pharmacogenomic (PGx) laboratory offering, enhancing its service portfolio [4] - The 2025 Quest Diagnostics Drug Testing Index indicates a significant increase in fentanyl positivity in random tests compared to pre-employment screenings [5]